Bioventus (BVS) Competitors $10.67 +0.15 (+1.43%) (As of 12/20/2024 05:15 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrends BVS vs. NVCR, NVST, NARI, IRTC, LIVN, ENOV, WRBY, CNMD, TNDM, and TMDXShould you be buying Bioventus stock or one of its competitors? The main competitors of Bioventus include NovoCure (NVCR), Envista (NVST), Inari Medical (NARI), iRhythm Technologies (IRTC), LivaNova (LIVN), Enovis (ENOV), Warby Parker (WRBY), CONMED (CNMD), Tandem Diabetes Care (TNDM), and TransMedics Group (TMDX). These companies are all part of the "medical equipment" industry. Bioventus vs. NovoCure Envista Inari Medical iRhythm Technologies LivaNova Enovis Warby Parker CONMED Tandem Diabetes Care TransMedics Group Bioventus (NYSE:BVS) and NovoCure (NASDAQ:NVCR) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, community ranking, earnings, media sentiment, institutional ownership, analyst recommendations, profitability, dividends and risk. Which has stronger valuation and earnings, BVS or NVCR? Bioventus has higher earnings, but lower revenue than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than Bioventus, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioventus$555.06M1.56-$156.23M-$0.61-17.49NovoCure$577.74M5.77-$207.04M-$1.40-22.00 Do institutionals and insiders hold more shares of BVS or NVCR? 62.9% of Bioventus shares are held by institutional investors. Comparatively, 84.6% of NovoCure shares are held by institutional investors. 32.9% of Bioventus shares are held by insiders. Comparatively, 6.3% of NovoCure shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Do analysts rate BVS or NVCR? Bioventus presently has a consensus price target of $15.00, indicating a potential upside of 40.58%. NovoCure has a consensus price target of $32.67, indicating a potential upside of 6.06%. Given Bioventus' higher possible upside, equities analysts plainly believe Bioventus is more favorable than NovoCure.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bioventus 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67NovoCure 0 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.67 Does the media prefer BVS or NVCR? In the previous week, Bioventus had 4 more articles in the media than NovoCure. MarketBeat recorded 7 mentions for Bioventus and 3 mentions for NovoCure. Bioventus' average media sentiment score of 0.91 beat NovoCure's score of 0.22 indicating that Bioventus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bioventus 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NovoCure 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is BVS or NVCR more profitable? Bioventus has a net margin of -7.11% compared to NovoCure's net margin of -25.93%. Bioventus' return on equity of 15.61% beat NovoCure's return on equity.Company Net Margins Return on Equity Return on Assets Bioventus-7.11% 15.61% 4.01% NovoCure -25.93%-41.48%-12.74% Which has more risk and volatility, BVS or NVCR? Bioventus has a beta of 0.79, indicating that its share price is 21% less volatile than the S&P 500. Comparatively, NovoCure has a beta of 0.75, indicating that its share price is 25% less volatile than the S&P 500. Does the MarketBeat Community favor BVS or NVCR? NovoCure received 446 more outperform votes than Bioventus when rated by MarketBeat users. Likewise, 63.72% of users gave NovoCure an outperform vote while only 62.50% of users gave Bioventus an outperform vote. CompanyUnderperformOutperformBioventusOutperform Votes3062.50% Underperform Votes1837.50% NovoCureOutperform Votes47663.72% Underperform Votes27136.28% SummaryBioventus beats NovoCure on 11 of the 17 factors compared between the two stocks. Ad Insiders ExposedHas Trump Finally Gone Too Far?Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.Register For The Webinar To Discover Get Bioventus News Delivered to You Automatically Sign up to receive the latest news and ratings for BVS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BVS vs. The Competition Export to ExcelMetricBioventusSurgical & medical instruments IndustryMedical SectorNYSE ExchangeMarket Cap$865.92M$4.34B$5.14B$19.19BDividend YieldN/A44.57%5.09%3.62%P/E Ratio-17.4925.3790.0541.30Price / Sales1.5645.921,117.0017.58Price / Cash14.6443.4442.9621.28Price / Book3.817.094.785.32Net Income-$156.23M$13.64M$120.31M$989.88M7 Day Performance-3.26%-2.93%-1.92%-3.54%1 Month Performance-7.22%0.28%11.50%-3.68%1 Year Performance107.18%40.76%30.59%12.14% Bioventus Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BVSBioventus3.6174 of 5 stars$10.67+1.4%$15.00+40.6%+104.8%$865.92M$555.06M-17.491,200Analyst UpgradePositive NewsNVCRNovoCure2.4915 of 5 stars$32.71-2.1%$32.67-0.1%+138.4%$3.54B$577.74M-23.861,453NVSTEnvista3.9074 of 5 stars$19.55+0.4%$20.65+5.6%-21.1%$3.36B$2.50B-2.5112,800Positive NewsNARIInari Medical3.3112 of 5 stars$55.19-0.7%$58.89+6.7%-11.9%$3.23B$574.50M-41.181,300Analyst ForecastInsider TradeIRTCiRhythm Technologies3.0956 of 5 stars$89.42+3.5%$107.82+20.6%-14.3%$2.80B$492.68M-17.782,000Analyst ForecastLIVNLivaNova3.626 of 5 stars$50.11-2.7%$69.17+38.0%-4.4%$2.72B$1.24B122.622,900Analyst UpgradePositive NewsENOVEnovis2.9726 of 5 stars$46.49+0.8%$67.00+44.1%-21.5%$2.60B$2.00B-21.396,550Positive NewsWRBYWarby Parker1.5732 of 5 stars$24.31+2.9%$20.73-14.7%+99.1%$2.47B$669.77M-87.523,491Insider TradeCNMDCONMED4.6139 of 5 stars$71.67-1.2%$79.80+11.3%-36.7%$2.21B$1.29B17.234,000Positive NewsTNDMTandem Diabetes Care4.6384 of 5 stars$33.18+1.6%$53.81+62.2%+30.3%$2.18B$747.72M-16.922,400Positive NewsTMDXTransMedics Group4.0377 of 5 stars$64.29+0.0%$126.80+97.2%-20.1%$2.16B$241.62M68.36210Analyst Forecast Related Companies and Tools Related Companies NovoCure Alternatives Envista Alternatives Inari Medical Alternatives iRhythm Technologies Alternatives LivaNova Alternatives Enovis Alternatives Warby Parker Alternatives CONMED Alternatives Tandem Diabetes Care Alternatives TransMedics Group Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:BVS) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bioventus Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bioventus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
